A Human Protein Atlas for Normal and Cancer Tissues Based on Antibody Proteomics

Department of Biotechnology, AlbaNova University Center, Royal Institute of Technology (KTH), SE-106 91 Stockholm, Sweden.
Molecular &amp Cellular Proteomics (Impact Factor: 6.56). 01/2006; 4(12):1920-32. DOI: 10.1074/mcp.M500279-MCP200
Source: PubMed


Antibody-based proteomics provides a powerful approach for the functional study of the human proteome involving the systematic generation of protein-specific affinity reagents. We used this strategy to construct a comprehensive, antibody-based protein atlas for expression and localization profiles in 48 normal human tissues and 20 different cancers. Here we report a new publicly available database containing, in the first version, approximately 400,000 high resolution images corresponding to more than 700 antibodies toward human proteins. Each image has been annotated by a certified pathologist to provide a knowledge base for functional studies and to allow queries about protein profiles in normal and disease tissues. Our results suggest it should be possible to extend this analysis to the majority of all human proteins thus providing a valuable tool for medical and biological research.

Download full-text


Available from: Hanna Tegel,
  • Source
    • "The inset shows the expression of the three galectin-9 splice variants. (B) Images of immunohistochemical staining of the galectins with detectable mRNA expression in NSCLC [27]. (C) Western blot analysis of galectin-9 isoform expression in NSCLC tumor tissue from 5 different patients. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Approximately 30-40% of the patients with early stage non-small cell lung cancer (NSCLC) will present with recurrent disease within two years of resection. Here, we performed extensive galectin expression profiling in a retrospective study using frozen and paraffin embedded tumor tissues from 87 stage I/II NSCLC patients. Our data show that galectin mRNA expression in NSCLC is confined to galectin-1, -3, -4, -7, -8, and -9. Next to stage, univariable Cox regression analysis identified galectin-1, galectin-9FL and galectin-9Δ5 as possible prognostic markers. Kaplan-Meier survival estimates revealed that overall survival was significantly shorter in patients that express galectin-1 above median levels, i.e., 23.0 (2.9-43.1) vs. 59.9 (47.7-72.1) months (p = 0.020) as well as in patients that express galectin-9Δ5 or galectin-9FL below the median, resp. 59.9 (41.9-75.9) vs. 32.8 (8.7-56.9) months (p = 0.014) or 23.2 (-0.4-46.8) vs. 58.9 (42.9-74.9) months (p = 0.042). All three galectins were also prognostic for disease free survival. Multivariable Cox regression analysis showed that for OS, the most significant prognostic model included stage, age, gal-1 and gal-9Δ5 while the model for DFS included stage, age and gal-9Δ5. In conclusion, the current study confirms the prognostic value of galectin-1 and identifies galectin-9Δ5 as novel potential prognostic markers in early stage NSCLC. These findings could help to identify early stage NSCLC patients that might benefit most from adjuvant chemotherapy.
    PLoS ONE 09/2014; 9(9):e107988. DOI:10.1371/journal.pone.0107988 · 3.23 Impact Factor
  • Source
    • "We found that investigators involved in generating the IL32 antibody used Ensembl database as their source for the IL32 sequences instead of NCBI. The IL32 antibody supplied by Novus Biologicals has been used to examine an assortment of different tissues and diseases as part of the Human Protein Atlas project [22]. Related to their study, the Protein Atlas project provides (a) a list of the IL32 variant sequences that match the antigen sequence and (b) a direct link for convenient retrieval of the matching variant sequences, available through the Ensembl database. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Triple negative breast cancer (TNBC) and often basal-like cancers are defined as negative for estrogen receptor, progesterone receptor and Her2 gene expression. Over the past few years an incredible amount of data has been generated defining the molecular characteristics of both cancers. The aim of these studies is to better understand the cancers and identify genes and molecular pathways that might be useful as targeted therapies. In an attempt to contribute to the understanding of basal-like/TNBC, we examined the Gene Expression Omnibus (GEO) public datasets in search of genes that might define basal-like/TNBC. The Il32 gene was identified as a candidate. Findings Analysis of several GEO datasets showed differential expression of IL32 in patient samples previously designated as basal and/or TNBC compared to normal and luminal breast samples. As validation of the GEO results, RNA and protein expression levels were examined using MCF7 and MDA MB231 cell lines and tissue microarrays (TMAs). IL32 gene expression levels were higher in MDA MB231 compared to MCF7. Analysis of TMAs showed 42% of TNBC tissues and 25% of the non-TNBC were positive for IL32, while non-malignant patient samples and all but one hyperplastic tissue sample demonstrated lower levels of IL32 protein expression. Conclusion Data obtained from several publically available GEO datasets showed overexpression of IL32 gene in basal-like/TNBC samples compared to normal and luminal samples. In support of these data, analysis of TMA clinical samples demonstrated a particular pattern of IL32 differential expression. Considered together, these data suggest IL32 is a candidate suitable for further study.
    BMC Research Notes 08/2014; 7(1):501. DOI:10.1186/1756-0500-7-501
  • Source
    • "Peptide and protein identifications are mapped to a comprehensive reference protein database (for the latest human builds, the searched database is a combination of UniProtKB/Swiss-Prot, Ensembl, and sequences from the International Protein Index (IPI)), and postprocessed using the TPP [72]. It also annotates each protein and peptide with supporting data, such as genome mappings, sequence alignments, links to different databases, such as GPMDB or the Human Protein Atlas [73], uniqueness of peptide– protein mappings, observability of peptides, predicted observable peptides, estimated protein abundances and crossreferences to other databases, such as RefSeq, UniGene and UniProt. All the processed results are loaded into SBEAMS (systems biology experiment analysis management system) proteomics that is a proteomics analysis database built as a module under the SBEAMS framework. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Compared to other data intensive disciplines such as genomics, public deposition and storage of mass spectrometry (MS)-based proteomics data is still less developed due to, among other reasons, the inherent complexity of the data and the variety of data types and experimental workflows. In order to address this need several public repositories for MS proteomics experiments have been developed, each with different purposes in mind. The most established resources are the Global Proteome Machine Database (GPMDB), PeptideAtlas and the PRoteomics IDEntifications (PRIDE) database. Additionally, there are other useful (in many cases recently developed) resources such as ProteomicsDB, MassIVE, Chorus, MaxQB, PASSEL, MOPED and the Human Proteinpedia. In addition, the ProteomeXchange consortium has been recently developed for enabling a better integration of public repositories and the coordinated sharing of proteomics information, maximizing its benefit to the scientific community. Here, we will review each of the major proteomics resources independently and some tools that enable the integration, mining and reuse of the data. We will also discuss some of the major challenges and current pitfalls in the integration and sharing of the data.This article is protected by copyright. All rights reserved
    Proteomics 08/2014; 15(5-6). DOI:10.1002/pmic.201400302 · 3.81 Impact Factor
Show more